Potential use of aromatase inhibitors in gynecology

Julie Lukic, Togas Tulandi
In: Expert Review of Obstetrics & Gynecology · 2006 · vol. 1(1) , pp. 41–47 · doi:10.1586/17474108.1.1.41 · W2021323947
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-28 ⓘ

This review examines the current and potential uses of aromatase inhibitors in gynecology, focusing on ovulation induction, endometriosis, and uterine myomata, extending their application beyond breast cancer treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Aromatase inhibitors have the potential to treat a wide spectrum of diseases where estradiol is required to manifest clinical symptoms. Their use was initially indicated for the treatment of hormone-dependent advanced postmenopausal breast cancer, but little is known regarding their role in gynecology. This review will address the current use of aromatase inhibitors in the treatment of ovulation induction, endometriosis and uterine myomata.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (49)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK